Fig. 4From: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyChange in monthly migraine days A) during 12 weeks and B) at 4 weeks by sex. LSM, least-squares mean; SE, standard error. aP < 0.001 vs placeboBack to article page